2024-09-22 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes medicines for the treatment of life-threatening diseases.

**1. Performance vs. S&P 500:**

* **Cumulative return of GILD:** -12.88%
* **Cumulative return of S&P 500 (VOO):** 132.46%
* **Difference in returns:** -145.34%
* **Relative divergence:** 6.47% (This means GILD has underperformed the S&P 500 significantly and its current performance sits at the 6.47th percentile compared to its historical performance relative to the S&P 500.)

**2. Recent Price Action:**

* **Closing price:** $83.94
* **5-day moving average:** $83.69
* **20-day moving average:** $80.50
* **60-day moving average:** $75.35
* **Conclusion:** GILD is currently trading above all its moving averages, suggesting a short-term bullish momentum.

**3. Technical Indicators:**

* **RSI:** 76.22 (Overbought)
* **PPO:** 0.25 (Positive but close to zero)
* **Delta_Previous_Relative_Divergence:** 1.17 (Positive, indicating potential short-term upward momentum)
* **Expected_Return:** 18.36% (This represents the maximum estimated return over 5 years based on current investment amount)

**4. Recent Earnings and Outlook:**

* **Last reported EPS:** $1.29 (Aug 8th, 2024)
* **Last reported Revenue:** $6.95 Billion (Aug 8th, 2024)
* **Analyst estimates:** 
    * **EPS:** N/A (No available data)
    * **Revenue:** N/A (No available data)

**Analysis of recent earnings:**

* The latest reported earnings of $1.29 EPS and $6.95B revenue indicate a positive trend compared to previous quarters, though further comparison with analyst estimates is needed to gauge the performance against expectations.

**5. Overall Analysis:**

* GILD has significantly underperformed the S&P 500 in the long term.
* Short-term momentum is positive, as the stock is trading above its moving averages and the Delta_Previous_Relative_Divergence shows an upward trend.
* However, the RSI suggests that GILD is currently overbought, implying potential for a correction. 
* The PPO is positive but close to zero, suggesting a neutral trend.
* The latest earnings were strong, but without comparing to analyst expectations, a definitive evaluation is not possible. 
* It is important to conduct further analysis, including a thorough examination of the company's financial health, competitive landscape, and future prospects, to determine a suitable investment strategy.

**6. Conclusion:**

GILD presents a mixed picture with both positive and negative aspects. The company's long-term performance has been disappointing, but recent price action and earnings show short-term strength. However, the overbought RSI and the lack of analyst estimates for the latest earnings warrant caution. Investors should proceed with caution and conduct thorough research before making any investment decisions. 
